Bio-Techne (TECH) balance sheet and financial health
TrendArc score 46 of 100 · Health 5.9 · Momentum 7.0 · Moat 3.9 · scored Nov 17, 2026 · How the score works
Cash and short-term investments less borrowings, September 30, 2026
$150 million more cash than borrowings
Bio-Techne held $350 million of cash and short-term investments against $200 million of borrowings on September 30, 2026. Its lease liabilities, shown apart from borrowings, were $86 million. In the fiscal year to June 2026 its operating income covered its interest 26.2 times.
Borrowings to equity
0.09
$200M of borrowings on $2.17B of equity, Sep 2026
Interest cover
26.2x
operating income over interest, fiscal year to June 2026
Return on invested capital
5.1%
latest quarter to September 2026, annualised; the stock card's measure
Cash and borrowings at each fiscal year end
What the balance sheet holdsSeptember 30, 2026
"Other liabilities" is total liabilities less borrowings and lease liabilities; "Property, goodwill and other" is total assets less the current assets and long-term investments.
Balance sheet, the last 10 fiscal year ends
| Fiscal year end | Latest Sep 2026 | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash and short-term investments | 0.35 | 0.26 | 0.16 | 0.15 | 0.20 | 0.25 | 0.23 | 0.27 | 0.17 | 0.18 | 0.16 |
| Receivables | 0.20 | 0.22 | 0.21 | 0.24 | 0.22 | 0.19 | 0.15 | 0.12 | 0.14 | 0.12 | 0.12 |
| Inventory | 0.20 | 0.20 | 0.19 | 0.18 | 0.17 | 0.14 | 0.12 | 0.10 | 0.09 | 0.09 | 0.06 |
| Other current assets | 0.07 | 0.07 | 0.05 | 0.04 | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 |
| Total current assets | 0.82 | 0.74 | 0.61 | 0.62 | 0.62 | 0.61 | 0.51 | 0.52 | 0.41 | 0.40 | 0.35 |
| Long-term investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total assets | 2.64 | 2.59 | 2.56 | 2.70 | 2.64 | 2.29 | 2.26 | 2.03 | 1.88 | 1.59 | 1.56 |
| Liabilities and equity | |||||||||||
| Current liabilities | 0.36 | 0.16 | 0.18 | 0.16 | 0.13 | 0.18 | 0.15 | 0.11 | 0.10 | 0.08 | 0.14 |
| Borrowings | 0.20 | 0.20 | 0.35 | 0.32 | 0.35 | 0.26 | 0.34 | 0.36 | 0.51 | 0.34 | 0.34 |
| Lease liabilities | 0.09 | 0.09 | 0.10 | 0.10 | 0.10 | 0.07 | 0.08 | 0.08 | — | — | — |
| Total liabilities | 0.47 | 0.48 | 0.64 | 0.64 | 0.67 | 0.59 | 0.69 | 0.65 | 0.72 | 0.51 | 0.61 |
| Shareholders' equity | 2.17 | 2.11 | 1.92 | 2.07 | 1.97 | 1.70 | 1.56 | 1.38 | 1.17 | 1.08 | 0.95 |
| Financial health | |||||||||||
| Cash less borrowings | 0.15 | 0.06 | -0.18 | -0.17 | -0.15 | -0.01 | -0.11 | -0.09 | -0.34 | -0.16 | -0.19 |
| Borrowings to equity | 0.09 | 0.09 | 0.18 | 0.15 | 0.18 | 0.15 | 0.22 | 0.26 | 0.43 | 0.31 | 0.36 |
| Interest cover | — | 26.2x | 12.0x | 13.1x | 26.7x | 26.2x | 17.0x | 8.2x | 6.8x | 13.4x | 16.4x |
Interest cover is operating income over interest expense, for full fiscal years. Minority interests and other is total assets less total liabilities and shareholders' equity (calculated by TrendArc). Company filings as standardised by Tiingo; borrowings and lease liabilities told apart with the lines the company files on SEC EDGAR, and a dash where the two cannot be told apart. Rebuilt nightly.
Bio-Techne against its peers
| Company | Cash less borrowings | Borrowings to equity | Interest cover | Return on invested capital |
|---|---|---|---|---|
| Bio-TechneTECH | +$150M | 0.09 | 26.2x | 5.1% |
| IlluminaILMN | -$452M | 0.57 | 8.0x | 16.4% |
| Mettler ToledoMTD | -$1.97B | 26.06 | 16.1x | 48.2% |
| Agilent TechnologiesA | -$2.19B | 0.54 | 13.2x | 13.2% |
| Charles River LaboratoriesCRL | -$2.24B | 0.76 | 0.2x | 21.9% |
| WatersWAT | -$4.54B | 0.34 | 11.5x | 1.6% |
| IQVIAIQV | -$13.6B | 2.41 | 3.0x | 6.4% |
Each company's newest balance sheet; borrowings leave lease liabilities out; interest cover for its newest fiscal year; return on invested capital is the stock card's measure. A dash where a measure does not apply.
Next
Follow Bio-Techne with a free account.
A watchlist, price alerts and saved chart layouts. No card needed.
Sign up freeNo forecast, no recommendation. This page describes Bio-Techne from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Nov 17, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.
The TrendArc score, from 0 to 100, combines three pillars measured from published data, Health (business quality over the last twelve months), Momentum (the price against its moving averages, its 52-week high and the market) and Moat (durability over five years), with the share price's long-run trend. It describes the company as it stands today. It is not a forecast or a recommendation.